ABCL: AbCellera Biologics Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
151 institutions reported holding $886.69M of AbCellera Biologics Inc. on Form 13F (138 the quarter before). 39 opened a new position and 27 sold out. Shares held by institutions: -8%.
| Largest holders | Shares | Value |
|---|---|---|
| BAKER BROS. ADVISORS LP | 33,012,138 | $259.15M |
| Capital World Investors | 13,588,349 | $106.67M |
| TWO SIGMA INVESTMENTS, LP | 10,437,431 | $81.93M |
| TD Waterhouse Canada Inc. | 9,568,149 | $72.62M |
| BANK OF AMERICA CORP /DE/ | 6,141,539 | $48.21M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4,317,206 | $33.89M |
| ArrowMark Colorado Holdings LLC | 4,105,095 | $32.22M |
| BlackRock, Inc. | 3,805,309 | $29.87M |
| Driehaus Capital Management LLC | 2,864,729 | $22.49M |
| TUDOR INVESTMENT CORP ET AL | 2,063,191 | $16.20M |
Clinical trial readouts
1 Phase 2 or 3 trials by AbCellera Biologics Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-02 (est.) | ABCL635 | Vasomotor Symptoms Associated With Menopause | Phase 1/2 | 136 | Enrollment complete | NCT07118891 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.